Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
5.58
-0.57 (-9.27%)
Jul 29, 2025, 4:00 PM - Market closed
Personalis Revenue
Personalis had revenue of $20.61M in the quarter ending March 31, 2025, with 5.53% growth. This brings the company's revenue in the last twelve months to $85.69M, up 15.57% year-over-year. In the year 2024, Personalis had annual revenue of $84.61M with 15.15% growth.
Revenue (ttm)
$85.69M
Revenue Growth
+15.57%
P/S Ratio
4.46
Revenue / Employee
$374,210
Employees
229
Market Cap
492.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 84.61M | 11.13M | 15.15% |
Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 57.37B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
PSNL News
- 7 days ago - Personalis to Announce Second Quarter 2025 Financial Results - Business Wire
- 11 days ago - Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 20 days ago - Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - Business Wire
- 2 months ago - Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO - Business Wire
- 2 months ago - New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse - Business Wire
- 2 months ago - Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection - Business Wire
- 2 months ago - Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference - Business Wire
- 3 months ago - Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript - Seeking Alpha